Source: International Congress 2018 – Drug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Borisov (Moscow, Russian Federation), A. Filippov (Moscow, Russian Federation), T. Ivanushkina (Moscow, Russian Federation), D. Ivanova (Moscow, Russian Federation), Y. Garmash (Moscow, Russian Federation). Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up. 3671

Member's Comments

No comment yet.

Related content which might interest you: When do we extend the treatment of tuberculosis (TB) more than 6 months? Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Repeat testing of ELISpot-positive TB contacts at 32 to 36 months post-exposure Source: Annual Congress 2010 - Immune responses for the diagnosis of tuberculosis Year: 2010 Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Upper age limit for bronchiolitis: 12 months or 6 months? Source: Eur Respir J 2012; 39: 787-788 Year: 2012 Upper age limit for bronchiolitis: 12 months or 6 months? Source: Eur Respir J 2012; 39: 788-789 Year: 2012 Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007 Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Tolerance to rifampicine (RIF) 4 months vs. isoniazid (INH) 6 months for latent tuberculosis infection (LTBI) Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice Source: Eur Respir J, 53 (2) 1801128; 10.1183/13993003.01128-2018 Year: 2019 Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020 Year: 2021 Pulmonary sequelae in patients with COVID-19: results after 3 months of follow-up Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Outcomes of level 1 Covid-19 inpatients at six months Source: Virtual Congress 2021 – COVID - 19 epidemiology Year: 2021 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 The evolution of tuberculosis incidence in romanian children (0-14 years) in the last ten years Source: Eur Respir J 2002; 20: Suppl. 38, 534s Year: 2002 Clinical indicators of treatment response to Mepolizumab at 12 weeks Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Mode of delivery and lung function of 16-19 year olds born at less than 29 weeks gestation Source: Virtual Congress 2020 – Respiratory disorders in neonatal and paediatric intensive care units: ventilation and chronic conditions Year: 2020 Adjunct treatment of pneumonia in children 6-18 years old using a hand held sputum induction device Source: Annual Congress 2012 - Airway infections in children: from risk factors to treatment Year: 2012 Validation of the asthma control questionnaire in children (6-16 years) Source: Annual Congress 2009 - Clinical advances in childhood asthma Year: 2009